Cognition Therapeutics Inc
NASDAQ:CGTX
Cognition Therapeutics Inc
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
Pipeline Focus: Cognition Therapeutics is now fully focused on advancing zervimesine (CT1812) for Alzheimer's disease and dementia with Lewy bodies (DLB), having concluded its dry AMD study early to conserve resources.
Financial Position: The company ended 2024 with $25 million in cash and $50 million in obligated NIH grant funds, extending its cash runway into Q4 2025.
Clinical Progress: Positive efficacy signals were reported in Phase II studies for both Alzheimer's and DLB, and the company is preparing for end-of-Phase II FDA meetings in both indications.
Cost Management: Early termination of the dry AMD trial reduced expenses and allowed increased investment in core Alzheimer's and DLB programs.
Partnering Efforts: Active business development is ongoing to secure non-dilutive funding, with strong interest from potential partners, though no deals have been finalized.
NASDAQ Compliance: Cognition received a 6-month grace period to regain compliance with NASDAQ's minimum bid requirement, confident it will meet the standard with upcoming milestones.
